Recombinant Human IL3RA, Fc-His tagged

• Cat.No.: IL3RA-3248H
• Product Overview: Recombinant Human IL3RA (NP_002174.1) extracellular domain (Met 1-Arg 305), fused with the polyhistidine-tagged Fc region of human IgG1 at the C-terminus, was produced in Human Cell.

Specification

• Source: Human Cells
• Species: Human
• Tag: His&Fc
• Form: Lyophilized from sterile PBS, pH 7.4
• Molecular Mass: The recombinant human IL3RA/Fc is a disulfide-linked homodimer. The reduced monomer comprises 535 amino acids and has a predicted molecular mass of 61 kDa. As a result of glycosylation, the apparent molecular mass of rh IL3RA/Fc monomer is approximately 80-90 kDa in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70oC.
• Storage: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Protein length: Met1-Arg305

Gene Information

• Gene Name: IL3RA interleukin 3 receptor, alpha (low affinity) [ Homo sapiens ]
• Official Symbol: IL3RA
• Gene ID: 3563
• mRNA Refseq: NM_002183
• Protein Refseq: NP_002174
• MIM: 308385
• UniProt ID: P26951

Reviews

07/24/2022

In special environment, good stability.

05/25/2022

Good crystallization property and good effect.

06/29/2021

Has the expected biological activity, such as enzyme activity and receptor binding activity, and so on.

Q&As

Can Il3ra be personalized?

The feasibility of personalized therapy depends on the specific disease type and patient situation, and more research is needed to determine the application of personalized therapy to Il3ra.

Does Il3ra have clinical application prospects? What are the prospects?

Il3ra has certain promise in clinical application, especially in the treatment of immune-related diseases.

What is the action mechanism of Il3ra?

Regulates the proliferation and differentiation of immune cells by binding to its interacting cytokine IL-3, and plays a role in regulating the function of the immune system.

How is the clinical trial of Il3ra progressing?

Clinical trials of recombinant Il3ra have been conducted in different disease areas. At present, some early trials show its potential in the treatment of certain diseases, but more research is needed to verify its efficacy and safety.

What is the specific effect of Il3ra on the immune system?

The Il3ra can regulate the proliferation and differentiation of different types of immune cells in the immune system, thus affecting the function of the immune system.

Does Il3ra have side effects?

Il3ra is generally well tolerated, but some minor side effects such as headache and nausea may occur. Serious side effects are rare.